Mark Watling

1.7k total citations
29 papers, 982 citations indexed

About

Mark Watling is a scholar working on Physiology, Psychiatry and Mental health and Pharmacology. According to data from OpenAlex, Mark Watling has authored 29 papers receiving a total of 982 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Physiology, 8 papers in Psychiatry and Mental health and 7 papers in Pharmacology. Recurrent topics in Mark Watling's work include Alzheimer's disease research and treatments (15 papers), Cholinesterase and Neurodegenerative Diseases (6 papers) and Dementia and Cognitive Impairment Research (5 papers). Mark Watling is often cited by papers focused on Alzheimer's disease research and treatments (15 papers), Cholinesterase and Neurodegenerative Diseases (6 papers) and Dementia and Cognitive Impairment Research (5 papers). Mark Watling collaborates with scholars based in Italy, United Kingdom and Belgium. Mark Watling's co-authors include Bruno P. Imbimbo, Madia Lozupone, Francesco Panza, Stefania Ippati, Vincenzo Solfrizzi, Claudia Balducci, A. Knight, Alexander Fisher, Stevan Shaw and Sophie Glatt and has published in prestigious journals such as Journal of Clinical Oncology, Brain and Annals of the Rheumatic Diseases.

In The Last Decade

Mark Watling

28 papers receiving 964 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Watling Italy 16 426 249 220 142 138 29 982
Mingchao Shi China 12 195 0.5× 135 0.5× 245 1.1× 80 0.6× 185 1.3× 37 864
Fabrizio Piazza Italy 21 796 1.9× 82 0.3× 367 1.7× 105 0.7× 200 1.4× 46 1.4k
Fengna Chu China 13 255 0.6× 232 0.9× 366 1.7× 87 0.6× 237 1.7× 28 959
Shahriar Nafissi Iran 23 216 0.5× 80 0.3× 626 2.8× 72 0.5× 139 1.0× 149 1.7k
Eduardo E. Valdez-Moráles Mexico 12 186 0.4× 69 0.3× 218 1.0× 77 0.5× 24 0.2× 25 889
László Kereskai Hungary 17 300 0.7× 70 0.3× 288 1.3× 56 0.4× 29 0.2× 73 1.2k
Graeme L. Fraser United States 22 223 0.5× 176 0.7× 490 2.2× 116 0.8× 15 0.1× 37 1.6k
Erik Lindström Sweden 22 322 0.8× 39 0.2× 349 1.6× 150 1.1× 24 0.2× 63 1.2k
Eva Moritz Switzerland 14 723 1.7× 162 0.7× 548 2.5× 213 1.5× 275 2.0× 16 1.3k
Raquel Guerrero‐Alba Mexico 12 173 0.4× 63 0.3× 203 0.9× 78 0.5× 23 0.2× 29 869

Countries citing papers authored by Mark Watling

Since Specialization
Citations

This map shows the geographic impact of Mark Watling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Watling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Watling more than expected).

Fields of papers citing papers by Mark Watling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Watling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Watling. The network helps show where Mark Watling may publish in the future.

Co-authorship network of co-authors of Mark Watling

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Watling. A scholar is included among the top collaborators of Mark Watling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Watling. Mark Watling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chanteux, Hugues, M. Macpherson, Christian Otoul, et al.. (2024). Overview of preclinical and clinical studies investigating pharmacokinetics and drug–drug interactions of padsevonil. Expert Opinion on Drug Metabolism & Toxicology. 20(8). 841–855.
2.
Otoul, Christian, M. Macpherson, Mark Watling, et al.. (2023). Clinical Bridging Studies and Modeling Approach for Implementation of a Patient Centric Sampling Technique in Padsevonil Clinical Development. The AAPS Journal. 26(1). 1–1. 4 indexed citations
3.
Imbimbo, Bruno P., Claudia Balducci, Stefania Ippati, & Mark Watling. (2022). Initial failures of anti-tau antibodies in Alzheimer’s disease are reminiscent of the amyloid-β story. Neural Regeneration Research. 18(1). 117–117. 33 indexed citations
4.
Bisceglia, Paola, Bruno P. Imbimbo, Madia Lozupone, et al.. (2022). Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?. Therapeutic Advances in Chronic Disease. 13. 374130181–374130181. 17 indexed citations
5.
Imbimbo, Bruno P., et al.. (2022). Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies. Pharmacological Research. 187. 106631–106631. 45 indexed citations
6.
Imbimbo, Bruno P., Stefania Ippati, Mark Watling, & Claudia Balducci. (2021). A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies. Alzheimer s & Dementia. 18(5). 1008–1037. 45 indexed citations
7.
8.
Ganjavi, Hooman, et al.. (2020). Striatum-Mediated Deficits in Stimulus-Response Learning and Decision-Making in OCD. Frontiers in Psychiatry. 11. 13–13. 4 indexed citations
9.
Panza, Francesco, Madia Lozupone, Davide Seripa, et al.. (2020). Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nature Reviews Neurology. 16(4). 213–228. 71 indexed citations
10.
Imbimbo, Bruno P., Stefania Ippati, & Mark Watling. (2020). Should drug discovery scientists still embrace the amyloid hypothesis for Alzheimer’s disease or should they be looking elsewhere?. Expert Opinion on Drug Discovery. 15(11). 1241–1251. 15 indexed citations
11.
Giacobbe, Peter, Enoch Ng, Daniel M. Blumberger, et al.. (2020). Interventional Psychiatry: An Idea Whose Time Has Come?. The Canadian Journal of Psychiatry. 66(3). 316–318. 8 indexed citations
12.
Imbimbo, Bruno P., et al.. (2020). Perspective: Is therapeutic plasma exchange a viable option for treating Alzheimer's disease?. Alzheimer s & Dementia Translational Research & Clinical Interventions. 6(1). e12004–e12004. 13 indexed citations
13.
Imbimbo, Bruno P., Madia Lozupone, Mark Watling, & Francesco Panza. (2020). Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives. Expert Opinion on Investigational Drugs. 29(9). 919–933. 25 indexed citations
14.
Glatt, Sophie, Peter C. Taylor, Iain B. McInnes, et al.. (2019). Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study. Annals of the Rheumatic Diseases. 78(8). 1033–1040. 49 indexed citations
15.
16.
Helmer, Eric, Mark Watling, Emma Jones, et al.. (2017). First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases. European Journal of Clinical Pharmacology. 73(5). 581–591. 13 indexed citations
17.
Fisher, Alexander, Mark Watling, Alexandra A. Smith, & A. Knight. (2010). Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 – 800 µg in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 48(12). 860–867. 45 indexed citations
18.
Fisher, Alexander, et al.. (2010). Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. International Journal of Clinical Pharmacology and Therapeutics. 48(2). 138–145. 48 indexed citations
19.
Fallon, Marie, et al.. (2010). Efficacy and safety of fentanyl pectin nasal spray versus immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain.. Journal of Clinical Oncology. 28(15_suppl). 9016–9016. 1 indexed citations
20.
Watling, Mark. (2004). The European Acquired Haemophilia Registry. Blood Coagulation & Fibrinolysis. 15(Supplement 1). S29–S29. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mingchao Shi Breakdown of academic impact, for papers by Fabrizio Piazza Breakdown of academic impact, for papers by Fengna Chu Breakdown of academic impact, for papers by Shahriar Nafissi Breakdown of academic impact, for papers by Eduardo E. Valdez-Moráles Breakdown of academic impact, for papers by László Kereskai Breakdown of academic impact, for papers by Graeme L. Fraser Breakdown of academic impact, for papers by Erik Lindström Breakdown of academic impact, for papers by Eva Moritz Breakdown of academic impact, for papers by Raquel Guerrero‐Alba
Rankless by CCL
2026